Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 23 Melanoma 21 Carcinoma, Renal Cell 21 Neoplasms 8 Lung Neoplasms 8 Colorectal Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Prostatic Neoplasms 7 Neoplasm Metastasis 6 Carcinoma, Transitional Cell 6 Carcinoma, Hepatocellular 6 Stomach Neoplasms 5 Rectal Neoplasms 5 Hodgkin Disease 5 Adenocarcinoma Of Esophagus 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Nasopharyngeal Carcinoma 4 Endometrial Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Thyroid Neoplasms 3 Pancreatic Neoplasms 3 Oropharyngeal Neoplasms 3 Multiple Myeloma 3 Leukemia, Myeloid, Acute 3 Esophageal Neoplasms 3 Colonic Neoplasms 3 Brain Neoplasms 3 Anus Neoplasms 3

Interventions

fludarabine 2 Cyclophosphamide 2 avelumab 1 Nivolumab 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × Nivolumab × 30 days × Clear all

NCT03134118 2026-05-15

NIVOTHYM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡